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ABSTRACT

Malignant hyperthermia/hyperpyrexia (MH) is a serious human skeletal
muscle disorder that manifests itself during general anaesthesia.
Currently, the most reliable method of diagnosing this disease is the in·
- vitro contracture test (IVCT). This procedure is both highly invasive for the
patient and expensive to perform. The skinned muscle fibre technique is
less invasive, and could possibly be used as an alternative diagnostic test
for MH.

In this study, skeletal muscle samples were obtained from 8 adults (age
23-54 years) undergoing elective surgery at Royal Perth Hospital. Six
patients were diagnosed as normal (controls) and two equivocal for MH
(MHE). Using the skinned muscle fibre technique (with exogenous Ca2+
. and sr2+), individual muscle fibre segments (10 from each biopsy) were
tested for differences in their contractile and regulatory proteins, and the
generated force per cross-sectional area (F/CSA). The results indicated
that the contractile and regulatory proteins of the ·MH E fibres displayed
altered functionality in comparison to the control fibres. The Type I MHE
fibres displayed greater sensitivity to Sr2+ (82%), whereas the Mixed MHE
fibres displayed greater sensitivity to Ca2+ (90%). However, the F/CSA
generated by the MHE fibres were overall less .than that of the control
-

.

fibres {43%), denoting statistical insignificance.

Ill

DECLARATION

I certify that this thesis does not incorporate without acknowledgment any
material previously submitted for a degree or diploma in any institution of
higher.eciucation; and that to the best of my knowledge and belief it does
not contain any material previously Mitten by another person except
where due reference is made in the text.

Signature_ _

SI

I

V

Date---------,
d- -7---------I I 00

IV

ACKNOWLEDGMENTS

Firstly, I would like to thank my suparvisor Dr Angus Stewart for guiding
me through the joys of preparing and completing a thesis. Dr Peter
Roberts (co-supervisor) and Dr Richard Brightwell for helping me with my
writing and giving general support. To Mr Phillip Morling (from the
Department of· Neuropathology, Royal Perth Hospital) for supplying me
with muscle samples.

To Eric, Bernie, Jane and Marie for helping me out in the lab and giving
me tips on how to go about things.

To Chris and Rhonda from the medical suite for doing my autoclaving, and
to Hugh, Helen and Bernie for also doing my autoclaving and just helping
out.

And finally, to my family for giving me ample support and encouragement
for when I needsd it the most.

. Thanks guys!

V

LIST OF TABLES

Table 2.1

Current chromosomal locations of human MH

29

Table 3.1

Parameters of normal human skeletal muscle

40

Table 4.1

Contractile parameters of control and MHE
skeletal muscle fibre types

47

TableA1.1

Kreb's-Ringer Solution

62

TableA1.2

Relaxing Solution I

62

TableA1.3

Relaxing Solution Ill

62

TableA1.4

Calcium Solution

63

TableA1.5

Strontium Solution

63

vi

LIST OF FIGURES

Figure 2.1

Two dimensional structure of a sarcomere

13

Figure2.2

Structure of the actin filament

14

Figure2.3

Structure of the myosin filament

14

Figure2.4

Top view of the ryanodine receptor

18

Figure2.5

Schematic model of the ryanodine receptor

18

Figure3.1

Equipment setup for the skinned muscle fibre
method

35

Figure 3.2

Individual muscle fibre tied with silk sutures

37

Figure3.3

Individual musde fibre mounted on stainless
steel forceps and pin of the transducer

37

Figure 3.4

Location of the stainless steel forceps and
transducer (and pin) in a multiple well solution
holder (carousel)

38

Figure4.1

Force-pea & ..pSr curves for a typical Type I
normal (control) muscle fibre

48

Figure4.2

Force-pea & -pSr curves for a typical Type I
MHE muscle fibre

48

Figure4.3

Force-pea & -pSr curves for a typical Type II
normal (control) muscle fibre

49

Force-pea & ..pSr curves for a typical Type II

49

Figure4.4

MHE muscle fibre

•,!

Figure4.5

Force-pea & -pSr curves for a Mixed normal
(control) muscle fibre

50

Figure4.6

Force-pea & -pSr curves for a Mixed MHE
muscle fibre

50

TABLE OF CONTENTS

Abstract

ii

Declaration

iii

Acknowledgments

iv

List of Tables

V

List of Figures

vi

CHAPTER 1: INTRODUCTION

1

1.1

Background to the Study

1

1.2 Significance of the Study

3

1.3 Purpose of the Study

3

1.4 Research Questions

4

1.5 Hypotheses

4

1.6 Definition of Terms/Abbreviations

5

CHAPTER 2: LITERATURE R:EVIEW
2.1

Introduction

9
9

2.2 History

10

2.3 Incidence

11

2.4 Trigger Agents

11

2.5 Skeletal Muscle Contractile Apparatus

13

2.6 Skeletal Muscle Fibre Types

16

2.7 Ryanodine Receptor

17

I
2.8 Signs & Symptoms

19

2.9 Treatment

21

2.10 Diagnosis

23

2. 11 Genetics

28

2.12 Prognosis

31

CHAPTER 3: MATERIALS & METHODS

32

3.1

Design

32

3.2

Muscle Biopsies

33

3.3

Ethical Considerations

34

3.4

Equipment

34

3.5

Procedure

35

3.6 Data Analysis

39

3.7

Limitations

41

CHAPTER 4: RESULTS

43

4.1

Results

43

4.2

Discussion

51

4.3 Conclusion

54

4.4

55

Further Developments

REFERENCES

56

APPENDIX 1

62

APPENDIX2

64

CHAPTER 1

INTRODUCTION

1.1

Background to the study

Malignant Hyperthermia is a pharmacogenetic disorder affecting human
skeletal muscle under the influence of the inhalant general anaesthetic
halothane, and the depolarising muscle relaxant suxamethonium. The
disease was first recognised in Australia in 1960 by Denborough and
Lovell, who discovered a family in which ten members died spontaneously
'Nhilst under general anaesthesia (Joffe, Savage & Silove, 1992;
Mccomas, 1996).

Studies by Walter (1981) and Joffe et al. (1992) determined that there was
a defect in the ryanodine receptors (calcium release channel) of the
sarcoplasmic reticulum (SR) within skeletal muscle. On exposure to
halothane or suxamethonium, these receptors release excess calcium into

the muscle fibres, resulting in skeletal muscle contracture. This prolonged
contraction of skeletal muscle results in hyperthermia, tachycardia and
cardiac arrest (Joffe et al., 1992).

Currently the most reliable method of diagnosing malignant hyperthermia
(MH) .is the in-vitro contracture test (IVCT): it is highly invasive for the

-·-
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patient and relatively expensive. The IVCT involves the removal of muscle
from the patient's thigh, and exposing it to controlled levels of halothane
and caffeine while continuously monitoring tension (Britt, 1979; Joffe et al.,
1992;

Serfas,

Bose,

Patel,

Wrogemann,

Phillips,

Maclennan

&

Greenburg, 1996). Research is currently underway to find a less invasive
technique than the IVCT of diagnosing the disease without compromising
accuracy (Takagi, Sunohara, Ishihara, Nonaka & Sugita, 1983).

The skinned muscle fibre technique involves the chemical (or mechanical)
removal of the cell membrane of the muscle fibre. The sarcoplasmic
reticulum (SR) is also disrupted ensuring that all the internal calcium is
removed. This therefore allows control over the environment within the
muscle cell (Britt, Frodis, Scott, Clements & Endrenyi, 1982; Fink,
Stephenson & Williams, 1990). The technique (which was used in this
study) has been applied to the testing of muscle biopsies, 1M1ere caffeine
is added to the muscle tissue. This is because caffeine has been found to
induce extreme skeletal muscle contraction (Takagi et al., 1983). This will
be discussed in detail later. However, in this skinned muscle fibre
technique, calcium and strontium ions are normally used to activate the
muscle fibre. The technique has been applied to many questions in muscle
physiology, notably Duchenne Muscular Dystrophy (Fink et al., 1990).

3

1.2

Significance of the Study

Current diagnostic techniques for MH are highly invasive, requiring a large
skeletal muscle biopsy to be taken from the patient's thigh in the operating
theatre, v.tiich is both painful to the patient and expensive to the
. community (Allen, Larach & Kunselman, 1998). Skinned fibre studies
require a much smaller biopsy (even needle biopsies have proven reliable)
and do not necessitate theatre time (Takagi et al., 1983). It is hoped that
this study will validate the use of a modified skinned muscle fibre
technique as a possible diagnostic test for MH. In addition, greater detail
will be revealed about the pathophysiology of MH, such as the effects of
calcium and strontium ions on the contractile apparatus.

1.3

Purpose of the Study

The purpose of this project is to examine the contractile responses/kinetics

of MH muscle to exogenous calcium and strontium ion activation in
comparison to that of normal human muscle. If significant differences are
!

~

identified then this technique may be ab!a to be employed diagnostically
with significant advantages to the patient and to hospital budgets. The
results may also aid in the understanding of the contradile and regulatory .
.

'

proteins of MH muscle and possibly determine why the MH muscle reacts
differently to certain pharmacological agents than does normal muscle.

....
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1.4

•

Research Questions

Are the functions of the contractile proteins, (myosin S1 subfragments)
affected by MH?

•

Are the functions of the regulatory proteins, (tropomyosin and troponin)
affected by MH?

•

Is the skinned muscle fibre method (employed in this study) a suitable
candidate for testing for MH?

1.5

•

Hypotheses

Individual MH muscle fibres display differing kinetics of contraction to
exogenous calcium and strontium ion activation than individual muscle
fibres in normal (control) human muscle.

•

The force per cross-sectional area generated by MH muscle fibres is
different to that of normal (control) muscle.

5

1.6

•

Definition of Terms/Abbreviations

Actin: a "thin" protein filament responsible for the contraction of skeletal
and cardiac muscle

•

Ala: alanine, an amino acid

• Arg: arginine, an amino acid
"

Contracture: permanent muscle contraction in the absence of nervous
stimulation

•

Cys: cysteine, an amino acid

•

Cytoskeleton: the internal skeleton in the cytosol of a cell

•

Depolarise: to make a cell's resting membrane potential more positive
(or less negative) as measured inside with respect to the outside

•

DHPR: dihydropyridine receptor, a protein molecule involved in the link
between the sarcoplasmic reticulum and transverse tubules in the
muscle

•

Dystrophin: a protein found in skeletal and cardiac muscle

•

Gly: glycine, an amino acid

•

Halothane: an inhalant anaesthetic widely used in general anaesthesia

•

His: histidine, an amino acid

•

Hyperthermialhyperpyrexia: an exceedingly high body temperature,
defined as being over 41°C

•

IV: intravenous administration

•

IVCT: in-vitro contracture test - exposing muscle biopsies to caffeine
and halothane to diagnose MH by monitoring the resultant contracture

6

•

Kinetic: pertaining to or producing motion

•

Malignant: to become progressively worse and to result in death

•

Malignant Hyperthermia/Hyperpyrexia (MH): a serious skeletal muscle
disorder arising during general anaesthesia that results in hyperthermia
and death

•

MHE: Malignant Hyperthermia Equivocal - a patient who tests positive
to either caffeine or halothane (borderline cases) but are clinically
treated as MHS

•

MHN: Malignant Hyperthermia Normal - a patient who tests negative to
caffeine and halothane to the IVCT

•

MHS: Malignant Hyperthermia Susceptible - a patient who tests
positive to caffeine and halothane to the IVCT

•

Myofibril: a subdivision of a muscle cell consisting of a series of

sarcomeres (contractile units)

•

Myosin: a "thick" protein filament responsible for the contraction of
skeletal and cardiac muscle

•

Pharmacogenetic: a genetic abnormality that is triggered by the
administration of a particutar drug or a combination of drugs

•

PSS: Porcine Stress Syndrome - the MH equivalent in certain breeds
of pig

•

RCT: ryanodine contracture test - using high purity ryanodine (98%) on
muscle biopsies to diagnose MH

•

Ryanodine: a nitrogenous substance (alkaloid) found in plants

7

•

Ryanodine receptor: a receptor mainly found in skeletal and cardiac
muscle (on the SR) that releases calcium into the contractile unit

•

RYR1: ryanodine receptor 1 gene - one of the possible genes located
on chromosome 19 that has been linked to some MH sufferers

•

S1 subfragment: another name for the globular heads of the myosin
filament necessary for the contradion of muscle

•

Sarcomere: the contractile unit of skeletal and cardiac muscle,
consisting of sliding filaments of adin and myosin

• Sarcoplasm: the cytoplasm (cytosol "fluid portion" and organelles) of a
muscle cell - also called myoplasm

• Sarcoplasmic Reticulum (SR): a membrane network similar to
.· endoplasmic reticulum surrounding each myofibril that contains
supplies of calcium ions for normal muscle contraction

•

Suxamethonium: a neuromuscular blocking agent causing muscle
relaxation that is commonly used in abdominal surgery - also called
succinylcholine chloride

•

Tropomyosin: a protein strand that covers the active site of an actin
molecule during relaxation

•

Troponin: three globular. proteins arranged over the tropomyosin and
actin molecule and contains the calcium receptor needed for
contraction

•

Type I fibre (slow-twitch): red coloured skeletal muscle that primarily

uses aerobic metabolism as an energy supply during contraction

:~------·----
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•

Type II fibre (fast-twitch): white coloured skeletal muscle that primarily
uses anaerobic metabolism as an energy supply during contraction

•

Vastus media/is: one of the four heads of the quadriceps muscle
located on the anteromedial aspect of the human femur

9

CHAPTER2

LITERATURE REVIEW

2.1

Introduction

Malignant hyperthermia/hyperpyrexia (MH) is a pharmacogenetic disorder
affecting human skeletal muscle fibres (Joffe et al., 1992). Inhalant general
anaesthetics such as halothane and depolarising muscle relaxants such
as suxamethonium, and their derivatives, are the agents that may trigger
an MH attack in malignant hyperthermia susceptible (MHS) and malignant
hyperthermia ·equivocal (MHE) individuals (McCarthy, Tong & Maclennan,
1998). Malignant hyperthermia is also present in certain breeds of swine

(Pietran and Lane/race), where an attack can be induced by both stress
and trigger agents. This is generally called Porcine Stress Syndrome
(PSS) (Joffe et al., 1992). In humans, MH is one of the major causes of
general anaesthetic related deaths, (approximately 4% of cases) (Lane,
1996). However, with the intravenous (IV) administration of the muscle
relaxant dantrolene, the death rate is significantly reduced (Healy, Quane,
Keating, Lehane, Heffron & McCarthy, 1996).

L _____________________ - - - - - - - - - - - - - - - - - - - - - -
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2.2

History

Malignant hyperthermia was first recognised in Australia in 1960 by
Denborough and Lovell, who discovered a family of which ten members
died after been given a triggering agent during general anaesthesia (Joffe
et al.,

1992;

Mccomas,

1996).

The

disease was

subsequently

incorporated into the International Classification of Diseases in 1983
(Merz, 1986).

In 1971, the in-vitro contracture test (IVCn using caffeine and halothane
was described at the First International Symposium on MH (Toronto,
Canada) in humans, and in 1975 the effects of dantrolene (a drug known
to reverse the symptoms), in pigs at the Second International Symposium
on MH (Katz, 1992). Dantrolene was approved by the US Food and Drug
Administration (FDA) in 1979 for use in humans and by 1983 the IVCT
was standardised to utilise caffeine and halothane on a biopsy removed
from a quadricep muscle. The patient was then diagnosed as either
malignant hyperthermia normal (see Section 2.10 p. 23) (MHN), MHS, or
MHE (European Malignant Hyperpyrexia Group, 1984; Katz, 1992).
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2.3

Incidence

MH occurs in 1 in 12,000 to 15,000 paediatric general surgical cases, and
1 in 40,000 to 100,000 adult general surgical cases (Joffe et al., 1992;

Sorrentino & Volpe, 1993; Pennington & Joeris, 1996; Dunn, 1997; Lake &
Maclennan, 1998). The most frequent age group for this disease is from 3
years of age through to 30 years of age, with males more commonly
affected (Lane, 1996). Porcine stress syndrome (PSS) occurs in up to 90%

of stress susceptible pigs (Joffe et al., 1992). Sporadic cases of MH have

occurred in thoroughbred racehorses and in greyhounds, cats, cattle and
_ even giraffes (Lane, 1996).

2.4

Trigger Agents

In humans, MH is precipitated by exposure to inhalant anaesthetics, such
as halothane, and depolarising muscle relaxants, such as suxamethonium
(McCarthy et al., 1998).

Halothane (Fluothane, ICI Pty Ltd) is a_ fluorinated hydrocarbon _that has
widespread use in general anaesthesia, due to -the fad that it causes little
irritation to the respiratory tract, and -usually does not initiate the cough
reflex. Halothane is usually combined with another inhalant anaesthetic,
nitrous oxide to maintain anaesthes,ia following induction (Galbraith,

L
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B1.1llock & Manias, 1994). Halothane is the most common and stronges-t
trigger in MHS individuals (Lane,

1996). The

other fluorinated

hydrocarbons related to halothane, which also trigger MH reactions are
isofl urane,

sevoflurane, enflurane,

desflurane,

and

methoxyflurane

(Galbraith et al., 1994; Malignant Hyperthermia Association of the United
States, 1997; MIMS, 1997).

Suxamethonium (Scoline, David Bull Pty Ltd) is a depolarising muscle
relaxant commonly used in abdominal surgery,

as most general

anaesthetics do not relax the abdominal muscles sufficiently (Galbraith et
al., 1994; MIMS, 1997; McCarthy et al., 1998). This drug is structurally
similar to the neurotransmitter acetylcholine. It acts as an acetylcholine
agonist on the nicotinic receptors of the motor end plate, by binding to the
motor end plate, inducing prolonged depolarisation and preventing
.

'

transmission of any neural impulses. This results in total muscle paralysis
(Galbraith et al., 1994). Normally after IV administration, the skeletal
· _muscles go into total spasm, then after a second or so the body should go
· totally flaccid. Hawever, .in MH individuals, the skeletal muscles remain
rigid (Galbraith

et al., 1994), which strongly indicates that the
··'

pathophysiology does· not involve the continual. depolarisation of the
muscle fibres.

In both . humans and pigs, halothane and · suxamethonium (and their
derivatives) cause the release·of calcium into the sarcoplasm, resulting in

13

increased metabolic activity and contracture of the skeletal muscles
(Galbraith et al., 1994). The defect lies in the ryanodine receptor (see
Section 2.6 p. 16) of the sarcoplasmic ret_iculum (SR) surrounding
individual myofibrils.

2.5

Skeletal Muscle Contractile Apparatus

Skeletal muscle is composed of many contractile units (sarcomeres) that
are necessary for muscle function . Sarcomeres contain two major
contractile proteins called actin (thin filaments) and myosin (thick
filaments). Other proteins involved are found associated with the Z line
(intermediate fi lament), the M line. The Z line is made up of the protein
connectin and it interconnects the actin filaments between each adjacent
sarcomere. The M line stabilises the myosin filaments in the centre of the
sarcomere. Anot~er protein titin, stabilises this structure by linking the
myosin filaments to the Z line (Figure 2.1) (Mccomas,
1996; Martini, 1998).

I band

A band

-·~-----~
"yosin

tin
Z line

Figure 2.1. Two dimensional structure of a sarcomere
(Source: Martini, 1998)
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Actin filaments measure approximately 6-Bnm wide and 1µm long. The
filament consists of troponin (3 subunits), tropomyosin and between 300400 actin molecules (Figure 2.2). The three troponin subunits consists of:
troponin T that attaches to the tropomyosin; troponin / that binds to the
actin molecule, and troponin C that binds to calcium (Mccomas, 1996).
Myosin filaments measure approximately 12nm wide and between 1.51.6µm long. This filament comprises of a single "tail" and two globular
cross-bridge "heads" (also called the S1 subfragments) (Figure 2.3)
(Martini, 1998).

Troponin

Actin
molecule

Figure 2.2. Structure of the actin filament
(Source: Martini, 1998)

Head
Figure 2.3. Structure of the myosin filament
(Source: Martini, 1998)

In a resting state, a sarcomere (defined as the functional unit of
contraction between two Z lines) measures approximately 2.6µm long, and
when viewed using optical microscopy, comprise of light and dark "bands"

15

consisting of the above filaments. The A band contains the zone of overlap
between the actin and myosin 1 the I band contains only actin, and the H
band contains only myosin and the M line. The naming of the A and I
bands were derived from the appearance viewed under polarised light.
Anisotropic (A band), light absorbing, and isotropic (I band), light
transmitting, were the tenns given (Martini, 1998).

The rationale of skeletal muscle contraction is still referred to as the
Sliding Filament Theory, devised by Huxley in the ear1y 1950s (Mccomas,
1996).

During contraction,

the myosin cross-bridge heads attach

themselves to specific binding sites on the actin molecules (active site),
causing the heads to pivot backwards, sliding the actin filaments towards
the M line, and then releasing. This is called "cross-bridge cyding". For
contraction to be initiated, calcium ions have to be released from the SR
through the ryanodine receptors, increasing th\3 intracellular concentration
from 10.aM to around 10~. Calcium binds to the troponin (troponin C)
which causes the troponin and tropomyosin to reflect away from the actin
binding site and allow the myosin heads to attach, permitting cross-bridge

cycling (Mccomas, 1996; Martini, 1998).
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2.6

Skeletal Muscle Fibre Types

In general, there are three distinct categories of muscle fibre types that
have varying properties. There are slow fibres {Type I), fast fibres (Type
II B) and intermediate fibres (Type IIA). Slow or red fibres have a slow
contraction speed (50-100msec) and a relatively small aoss sectional
diameter (10-50µm) (Martini, 1998). Its colouring is due to a high
myoglobin (muscle haemoglobin) content that has plentiful oxygen
reserves (Peachey, Adrian & Geiger, 1983). These fibres are primarily
used for prolonged contractions such as postural maintenance, therefore
they have many mitochondria that use aerobic metabolism (Peachey et al.,
1983). Fast or white fibres have a fast contraction speed of 10msec or less
and have a large cross sectional diameter (50-100µrn). These fibres have
a low myoglobin content and very few mitochondria, therefore they rely on
large glycogen reserves (anaerobic metabolism) for energy (Peachey et
al., 1983; Martini, 1998). These fibres produce powerful contractions for
activities such as sprinting and lifting, but fatigue rapidly (Martini, 1998).

Intermediate fibres are similar to fast fibres in appearance and
metabolism, however they do not fatigue as easily (Peachey et al., 1983;
Martini, 1998).
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2.7

Ryanodlne Receptor

The ryanodine receptor is the principal channel through '-Nhich calcium is
released from the sarcoplasmic reticulum (SR) into the sarcoplasm. The
naming of the receptor comes from the plant alkaloid ryanodine, as it was
found experimentally that this protein has a high affinity to these receptors

(Joffe et al., 1992).

The receptor is divided into four domains or radial channels that are
connected to a 2nm central channel, and has a four leaf clover
appearance (see Figure 2.4) (Joffe et al., 1992; Lane, 1996). The base or
foot of the receptor protrudes into the junctional membrane of the SR
(where the dihydropyridine (DHP) receptors are located). The N-terminal is
hydrophilic ("water loving") and protrudes into the sarcoplasm (see Figure
2.5). The central channel is the calcium release channel essential for the
contraction of skeletal muscle (Joffe et al., 1992; Lane, 1996). In MH the
ryanodine receptor stays open, subsequently causing prolonged release of
calcium into the muscle fibre (Galbraith et al., 1994). Why the receptor
stays open is as yet unknown.

18

Figure 2.4. Top view of the ryanodine receptor as viewed by an electron
microscope
(Source: Joffe et al. , 1992)

-<------

/

/-

--,

;>-·--......,:

Cytosol

SR
membrane

Interior

Figure 2.5. Schematic model of the ryanodine receptor
(Source: Sorrentino & Volpe, 1993)
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2.8

Signs & Symptoms

When an MHS individual i~ expos6d to halothane or suxamethonium, a
defect in the ryanodine receptor of the internal membrane of the muscle
fibre (sarcoplasmic reticulum) causes the release of calcium into the
skeletal muscle fibres, resulting in prolonged muscle contraction (Joffe et
al., 1992). This continual contraction of the skeletal muscles leads to
adenosine triphosphate (ATP) depletion. To overcome this, the body
compensates by rephosphorylating ATP from adenosine diphosphate
(ADP), thus resulting in excess heat production. Subsequently, aerobic
and anaerobic metabolism are accelerated in the skeletal muscles leading
to excess lactic acid levels (acidosis) (Joffe et al., 1992; Katz, 1992).
Eventually cell membranes break down causing the release of·myoglobin,
potassium and enzymes. If not treated, irreversible cell death

c.an

(Katz, 1992).

Early symptoms of an MH attack involve:

•

An increase in heart rate and pulse rate (tachycardia).

•

Rapid, shallow respirations (tachypnoea).

•

Skeletal muscle rigidity.

•

Increase in blood pressure (hypertension).

•

Initially flushed skin, then pale (cyanotic) and unusually warm.

•

Abnormal brain wave pattern (dysrhythmia).

•

Increase in end-tidal carbon dioxide (ETC02) levels.

occur
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The time scale of these events depends on the severity of the disease.

(Merz, 1986; Katz, 1992; Maclennan, 1992)

As an attack progresses, impaired coagulation and subsequent bleeding

from body orifices occurs, with pulmonary oedema, acidosis, high serum
myoglobin levels, hyperthennia (over 44°C), and masseter muscle spasm
(MMS) (Merz, 1986; Katz, 1992; Maclennan, 1992).

Finally, if treatment is delayed or unavailable, there is an increase in blood
potassium levels (hypeii<alaemia) and a decrease in blood pressure
(hypotension), heart rate and pulse rate (bradycardia) with subsequent
cardiac arrest (Merz, 1986; Katz, 1992). Death can occur within minutes
from ventricular failure and within hours from pulmonary oedema or the
inability to clot blood (coagulopathy). In the longer term, the disorder can
be fatal days later from neurological damage or myoglobin in the urine
(myoglobinurea), leading to renal failure (Maclennan, 1992; Ball &
Johnson, 1S93). HO\Y8ver, with the development of end-tidal carbon
dioxide (ETC~) analysers and other monitoring systems, an attack can be

detected eartier, and dantrolene subsequently administered (see Section
2.9 p. 19) (Maclennan, 1992; Lane, 1996).

MH has been desaibed in species other than humans and is common in
pigs (Maclennan, 1992). Porcine stress syndrome (PSS) is associated
with lean heavily muscled breeds, notably Pietran and Lane/race. It

was
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noted that when these breeds were subjected to enormous stress, such as
prior to slaughtering, they spontaneously died. Other causes of stress
included overheating, exercise, mating and transportation. This is a major
economic problem for the pork industry, as the meat produced is pale, soft
and pliable (Maclennan, 1992; Loke & Maclennan, 1998). The symptoms
of PSS are almost identical to that of human MH and include muscle
rigidity, acidosis, increased body temperature, hyperkalaemia, and cardiac
arrest (Britt, 1979; Jones & Round, 1990; Mccomas, 1996). However,
unlike humans, stress is the main trigger of an MH crisis rn pigs.

2.9

Treatment

Dantrolene sodium (Dantrium, Pharmacia & Upjohn) is the most effective
treatment for an MH attack if it is administered early intravenously (Merz,

.1986). Dantrolene is a muscle relaxant that reverses the effects of excess
calcium in the skeletal muscle fibres by paralysing SR fundion and closing
the calcium channels of the ryanodine receptor. Dantrolene does not
interfere with nervous transmission to the muscle, nor with the
depolarisation of the muscle membrane itself (Galbraith et al., 1994).

Should an attack occur during surgery, the following procedures must be
undertaken to ensure the safety of the patient:
•

Halt surgery.
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•

Discontinue triggering agents.

•

Administer intravenous (IV) dantrolene (within a 5-minute window
period) - Dose: 1mg/kg up to maximum of 1Omg/kg over a 15--minute
period.

•

Tum off vaporiser and change rubber tubing on anaesthesia machine.

•

Hyperventilate patient with 100% oxygen (02).

•

Reduce body temperature at several different sites: surface,
intravenously, intragastrically, intrarectally, and at the site of surgical
opening. If the body temperature is still high, then additional doses of
dantrolene can be administered.

•

IV potassium chloride to reduce the effects of hyperkalaemia.

•

IV mannitol to reverse any cerebral or muscle oedema, and to help

dislodge myoglobin from the nephrons.
•

If the surgery has to continue, then a trigger-free agent must be used,
such as nitrous oxide and oxygen (N20:02), narcotics, tranquilisers,
barbituates or non-depolarising muscle relaxants.

(Merz, 1986; Lane, 1996)

After the patient has been stabilised, a flare-up can occur on return to the
recovery room or in the ward. Therefore, the patient has to be closely
monitored for at least 24 hours in the intensive care unit (ICU) (Merz,
1986). Patient monitoring involves the following:
•

Body temperature, especially axillary temperature

•

Electrocardiogram (ECG)

I
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•

End-tidal CO2 (ETC02)

• Arterial oxygen saturation levels (pulse oximetry)
• Blood pressure
•

Skin circulation and appearance

•

Blood gas analysis

•

Urine output

•

Serum electroJytes, especially potassium

•

Blood pH

• Myoglobin levels
And the administration of oral dantrolene - Dose: 4mg/kg per day.
(Merz, 1986; Lane, 1996)

2.10

Diagnosis

The most commonly used test to diagnose MH in humans, is the in-vitro
.

.

'

contracture test (IVCT) or caffeine-halothane contracture test (CHCT). The
.abbreviallon IVCT will be used from now on. Both caffeine and halothane
have been shown to induce constant skeletal muscle contractions in
muscle biopsies in the laboratory (Joffe et al., 1992; Abraham, Adnet,
Glauber & Perel, 1998; Allen et al., 1998; Weppler et.al., 1998). There are
two methods of the IVCT - deemed the North American method and the
European method respectively.
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The European method of diagnosing MH was standardised in 1983
(European Malignant Hyperpyrexia Group, 1984). The protocol involves
taking a biopsy from one of the muscles of the quadriceps group including
a motor end point. The biopsy measures approximately 40mm long and
30mm wide. The muscle is then placed in Kreb's-Ringer solution (see
Appendix 1 Table A1.1 p.62) v.here it is to be transported to the diagnostic
laboratory. This solution mimics the extracellular ionic environment,
nonetheless the muscle has to be tested within a 5 hour period or it will
deteriorate beyond usefulness. When the muscle has been dissected into
smaller strips (measuring 25mm x 3mm), it is placed into an organ bath at
37°C and perfused with Kreb's-Ringer solution and equilibrated with
carbogen (mixture of 95% oxygen and 5% carbon dioxide), and stimulated
at a frequency of 0.2Hz. Three separate tests are performed.
1) Static caffeine
This invloves increasing the concentration of caffeine in the
perfusate from 0.25 millimol per litre (mmol L-1) to 4.0 mmol L-1
over a 3 minute period.
2) Static haloth,me
This involv<1s increasing the concentration of halothane in the
perfusate from 0.5%v/v to 3.0%v/v over a 3 minute period.
3) Dynamic halothane
This involves stretching the muscle at a oonstant rate for 1
minute, then increasing the halothane concentration from
0.5%v/v to 3.0%v/v, until muscle tension is sustained at 0.2g-wt.
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These three tests help to distinguish the MH status of the individual in the
following three categories:
1) Malignant hyperthennia susceptible (MHS)
This is where the start of contracture (thresholrl) is less than or
equal to 1.5mmol of caffeine, and is less than or equal to
2.2%v/v of halothane.
2) Malignant hyperthermia normal (MHN)
This is where the start of contracture is greater than or equal to
3mmol of caffeine without the contracture threshold .for
halothane being greater than or equal to 3%v/v.
3) Malignant hyperthermia equivocal (MHE)

This is vmere only the caffeine threshold (MHEc) or the
halothane threshold (MHEh) is reached, as per the MHS
concentrations. However, these people are clinically regarded

asMHS.
(European Malignant Hyperpyrexia Group, 1984)

The_North American method was standardised in 1987 (Larach, 1989) and
is similar to the European method. The main biopsy sites are the
quadriceps or the rectus abdominus, however a large mixed type 1/11
muscle (such as biceps brachii) can also be used. The biopsies measure
approximately 10-20mm long and 1-Smm wide. The organ bath and
solutions are the same as the European method, however the testing
protocols are different.

26

1) Halothane
The concentration of halothane in the perfusate increases from
2.7% to 3.3% over a period of 10 minutes.
2) Caffeine
The; concentration of caffeine in . the perfusate increases from
0.5 millimolar (mM) to 32mM over a period of 10 minutes.
3) ,Joint caffeine-halothane
This is an optional test performed by some laboratories and
involves the muscle being exposed to 1% halothane for 1O
minutes then increasing the concentration of caffeine from
0.25mM to 32mM.
The diagnosis for the North American method is also different as it does
not use equivocals (MHE) as an MH status. A positive result can be one of
the following:
1) If the start of contracture (threshold) for halothane is greater

than 0.2g-wt.
2) lfthe start of contracture (threshold) for 2mM caffeine is greater
than or equal to 0.2g~wt.
3) If the start of contracture (threshold) occurs at a caffeine
concentration of 1mM or less in the presence of 1% halothane.
(Larach, 1989; Lane, 1996).

The IVCT is a highly invasive technique as it involves the removal of a
substantial mass of skeletal muscle from either a quadriceps or abdominal

.,

.... .....
__
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muscle. This procedure is performed under a trigger-free general
anaesthetic for children (and pigs), as it is less traumatic, and under a
local anaesthetic for adults (Serfas et al., 1996). The testing procedure is
also expensive. False-positive and false-negative results have been
knovvn to occur, especially with the European method, as this protocol

uses the MHE category. As the North American method only distinguishes
people as either normal or susceptible, there is the less likelihood of
producing false results (Maclennan, 1992).

There is another form of the IVCT using the plant alkaloid, ryanodine. The
_ryanodine contradure test (RCT) has been used by the European
Malignant Hyperthermia Group since 1993 (Hopkins, Hartung, Wappler &

EMHG, 1998). The biopsy (measuring 15-30mm x 2-3mm x 2-3mm) is
removed from one muscle of the quadriceps group, usually the vastus
lateralis. Like the IVCT the muscle is transported in Kreb's-Ringer,
equilibrated with carbogen and testing performed within 5 hours.
· Ryanodine (98-99% pure) is ·then added in 1 micromol (µmol) and 2µmol
· •. concentrations, where three phases of contradure are observed.
1) Start of COl".ltracture in minutes. ·
·_ 2) Time (minutes) when the contracture reaches 0.2g-wt.
3) Time (minutes) YAlen the contracture reaches 1.0g-wt.
·11 has been found that MHS muscle contracts faster in these three phases
· than MHN muscle. The RCT can also redyce the number of equivocals to
either normal or susceptible, hence this· .test should. be .performed in

·.

:

. ,' .

.
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conjunction with the European IVCT (Weppler, Ro8\Y8r, Kochling, Scholz,
Steinfath & Schulte-am·Esch, 1996; Hopkins et al., 1998).

The main problem with the IVCT is that it cannot be used for screening the
general population due to the low prevalence of the disease, the cost of
performing the biopsies and the trauma of the procedure (Allen et al.,
1998). It is hoped in the future that a genetic test may be available for
humans (Abraham et al., 1998),

or a modified testing procedure requiring

very small amounts of muscle that can be collected by needle biopsy.

2.11

Genetics

Malignant hyperthermia is commonly inherited as an autosomal dominant
trait, but sporadic cases of autosomal recessiveness and codominance
have been known to occur (Denborough, 1998). Six chromosome localities
have been identified in human MH, the most common being expressed on
· chromosome 19. This chromosome contains the ryanodine receptor 1
gene (RYR1 ) on its long arm (q), where linkage studies have found a 50%
possibility that MH is connected to this gene (Lake, Tong, McCarthy &
Maclennan, 1998). At present, 17 ·point mutations have been located on
the RYR1 gene (Lane, 1996; Wallace, Wooldridge, Kingston, Harrison,
Ellis & Ford, 1996; Lake & Maclennan, 1998; Lake et al., 1998; Soto &
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Sopher, 1998). Table 2.1 shows all the current chromosomal locations and
the possible genes and mutations identified to these chromosomes.

Table 2.1. Current chromosomal locations of human MH
Chromosomal

Gene

Mutation

1Sq13.1

RYR1

17 point mutations including:
Arg615Cys; Gly2434Arg;
Arg614Cys; Gly314Arg;
Arg163Cys (wild type)

17q11.2-q24

DHPR-gamma subunits
(CACNLB1 & CACNLG)

Unidentified

Sodium channel alphasubunit (SCN4A)

Gly1306Ala

7q21.1

DHPR alpha 2/deltasubunit (CACNL2A)

Unidentified

3q13.1

Unidentified

Unidentifi •Kl

1q32

DHPR alpha 1-subunit
(CACNL1A3)

Arg1086His

5p.(short arm)

Unidentified

Unidentified

Location

(Source: Censier, Urwyler, Zorzato & Treves, 1998; Denborough, 1998; Loke &
Maclennan, 1998; Monsleurs, Van Broeckhoven, Martin, Van Hoof & Heytens, 1998)
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In pigs, PSS is an autosomal recessive disease, and is associated with a
single mutation in the RYR Arg615Cys gene on chromosome 6q (Joffe et
al., 1992; Shomer, Mickelson & Louis, 1995; Lane, 1996; Laver, Owen,
Junankar, Taske, Dulhunty & Lamb, 1997). The mutation in the RYR gene
contains the amino acid substitution of cystine for arginine. This
substitution is enough to alter the protein structure sufficiently to prevent
the ryanodine receptor from closing properly (Mccomas, 1996). However,
as this is a single point mutation, a genetic test is now available. The test
requires 50µ1 of whole blood, and can be performed quickly and accurately
(Maclennan, 1992).

MH has also been linked to oth~r neuromuscular diseases (NMDs). There
is a genetic link between MH and central core disease (CCD), as the gene
for CCD is close to the RYR1 gene on chromosome 19q (Denborough,
1998). CCD is an autosomal dominant disease and its clinical features
include foot deformities, forward curving of the spine (kyphoscoliosis),
congenital hip dislocation and joint con~ractures. Electron microscopic
analysis revealed that the contractile apparatus in CCD muscle showed
marked disintegration (Lake & Maclennan, 1998).

· ·MH may be related to two other NMDs, Duchenne muscular dystrophy
(DMD) and King-Denborough syndrome (KOS) (Wedel, 1992). DMD is a
sex-linked recessive disorder affecting young males, and the gene is
located on chromosome Xp21. This disease causes progressive muscle
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wasting due to the absence of the muscle protein dystrophin (Cummings,
1994). Those DMD patients who have suffered an MH-type reaction during
surgery usually test positive to the disease and account for approximately
4% of all positive IVCTs (Lane, 1996). KOS affects males and its clinical
features

include

a

short,

stocky

stature,

chest

abnormalmes,

kyphoscoliosis, a hump-back (thoracic kyphosis) and undescended testes
(cryptorchidism). It has been found that those KOS patients who have had
an MH crisis test positive to the disease (Lane, 1996).

2.12 Prognosis

The survival rate of MH in the 1990s is extremely high (96-97%). This is
due to a better awareness of the disease and the consistent use of
monitoring, by such means as blood gas analysis, body temperature and
ETCO, analysis (Mertz, 1986; Lane, 1996). Familiarity with the MH
protocols by surgical staff has led to the earlier cessation of trigger
anaesthetics and the administration of IV dantrolene (Lane, 1996).
HO\'\'ever, the IVCT still remains the only form of diagnosis for the disease
in humans. The genetics involved in human MH are complicated
compared to PSS, therefore a genetic test for humans is still a long way off
(Joffe et al., 1992).
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CHAPTER3

MATERIALS & METHODS

3.1

Design

The design used in this study consisted of the analysis of single skeletal
muscle fibres using exogenous calcium and strontium ion activation, and
the

subsequent

mathematical

analysis

of force-ion concenbation

relationships. The method involved the chemical removal of the cell
membrane from the single muscle fibre, thus leaving only the contractile
apparatus. The SR was also disrupted, ensuring that all the internal
calcium was removed to prevent any confounding of the results (Brill et al.,
1982; Fink et al. 1990). This method was used to examine the dynamics of
the contractile and regulatory proteins in both MH and control muscle. It is
also hoped that this study will indicate if another less invasive technique
could be used to test for MH without compromising accuracy.

. ··. •..
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3.2

Muscle Biopsies

Skeletal muscle biopsies (measuring 40mm x 30mm x 5mm) were
removed from the vastus medialis muscle under a regional anaesthetic by
RPH surgical staff. The MH status of the patient was unknown at this
stage. The muscle biopsy was transported in Kreb's-Ringer solution to the
Department of Neuropathology (Royal Perth Hospital) where it was divided
into three portions: one portion for the IVCT (according to the European
Malignant Hyperthermia Group protocol); one for histological analysis, and
the last portion for this study. Only after the biopsy had undergone testing
for this study was the result of the IVCT compared with the results
obtained here. Biopsies determined as MHN ..w,re used as the controls for
this present study.

The biopsies used for the study were then transported in a relaxing
solution containing 50% glycerol to prevent damage to the musde fibres
(see Appendix 1 p.62). Musde testing was delayed for approximately 4
days in order to remove any regional anaesthetic still remaining in the
tissue. This did not impinge on the viability of the sample.
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3.3

Ethical Considerations

The study was approved by both the Edith Cowan University Ethics
Committee and Royal Perth Hospital's Ethics Board. The muscle samples
used were obtained after \Mitten consent from the patient (see Appendix 2
p.64) on the day of admission.

3.4

Equipment

•

microdissecting surgical instruments

•

dissecting binocular microscopes - Carl Ziess Jena Citoval 2, Leica
Wild M3Z

• fibre optic 1OfN,/ cold light source
•

micro-force transducer and electrical amplifier/coupler

•

3-D micromanipulator

•

multiple well, rotary solution holder

•

Deknatel, 10/0 black silk suture

•

Macintosh LC 575, Maclab 2E, Maclab GP Amp, Maclab v3.5
ADlnstruments (see Figure 3.1)

•

Olympus digital camera
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Figure 3. 1.

3.5

Macintosh
LC 575

Equipment setup for the skinned muscle fibre method

Procedure

Ten individual muscle fibres were removed from 8 biopsies. The individual
muscle fibres were dissected from a muscle strip (measuring 10mm x
2mm x 2mm). Ir., a petri dish, the muscle strip was covered by a layer of
paraffin oil at 4°C in order to prevent the muscle from drying out.
Microdissecting instruments and a dissecting microscope illuminated by a
fibre optic cold light source were used to dissect free the individual muscle
fibres. Each fibre was tied with 10/0 black silk suture at each end, forming
a loop with the diameter of a 19 gauge needle (see Figure 3.2). The fibre
was then mounted onto the stainless steel forceps and pin of the
transducer (see Figures 3.3 & 3.4), where it was adjusted to optimal length
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for contraction by trial and error, and measured length by width (divisions)
using a graticule (8 divisions equated to 1mm).

The fibre was dipped in 2% Triton X-100 (detergent) in relaxing solution I
(Appendix 1 Table A1.2 p.62) for 10 minutes to render the membrane
permeable, and then into the weaker relaxing solution Ill (Appendix 1
Table A1 .3 p.62) for a further 60 seconds, where the force signal was set
to electrical zero. The fibre was subsequently tested at various
concentrations of calcium and strontium, from the weakest through to the
strongest concentration (Appendix 1 Tables A1.4 & A1.5 p.63). This is the
gradual or "stepping" increase in concentration to see where the muscle
begins to contract. When the fibre contracted it pulled against the pin of
the transducer. This altered the electrical resistance of the transducer,
causing a voltage change at the input stage of the GP Amp. The signal
was digitised by the Maclab computer system and displayed on the
computer screen as a continuous graph of force versus time. Force
maxima and minima were logged against ionic concentration for
subsequent analysis by fitting a mathematical equation to the data (Fink et

al., 1990). Experiments were performed at room temperature (22-24°C).
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Fibre
Muscle striQ
I

G

I

2mm

Figure 3.2. Individual muscle fibre (top) tied with silk sutures

Figure 3.3. Individual muscle fibre mounted on stainless steel
forceps (left) and pin of the transducer (right)

Carousel
Figure 3.4.

Location of the stainless forceps and transducer (and pin) in a multiple well solution holder (carousel)
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3.6

.Data Analysis

The datum points logged on Maclab v3.5 (Macintosh AD Instruments
scientific software) \N8re converted to Microsoft Excel format, 'Atlich was
then reinterpreted in DeltaPoint Delta Graph Pro 3.5 to produce plots of
the calcium concentration (pCa)- and strontium concentration (pSr)-force
relationships (see below). Curve parameters (affecting slope and lateral
shift - see Hill Equation p. 40) between MH equivocal (MHE) and normal
(control) data were analysed by paired Student t-test. Differences \Y8re
considered statistically significant if P<0.1. Values were represented as
mean ± standard error of the mean (S.E.M). Measured fibre width was
used to calculate force per cross-sectional area (F/CSA - see p. 41). The
data were categorised into two groups: controls and MHE.

pCa- pSr-force Relationships:
•

pCaso and pSrro equates to 50% of the maximum activated for
response. This value indicates the relative sensitivity of the contractile
apparatus to each activating ion.

•

pCa10 and pSr10 equates to 10% of the maximum activated force
response. This value indicates the activation threshold of the
contractile apparatus to each activating ion.

•

pCaro-pSrro is the difference in relative sensitivity of the contractile
apparatus to the two activating ions.

. (Stephenson, O'Callaghan & Stephenson, 1994)
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Hill Equation:
The Hill coefficients (nea and nsr) reflect the steepness of the curve (fitted
from the datum points) by the following equation:

where:

Pr = relative force
K = constant (as defined below)
x2• = concentration of Ca2• or sr2•

Ho\Y8ver the above equation was altered in order to calculate these
solutions. The calculation is as follows:

Parameters set by Fink et al., 1990 for normal human skeletal muscle
(Type I and II) are defined in the following table: .

. Table 3.1 Parameters of normal human skeletal muscle

nca
n5r
pCSsJ
pCa10
pSrso
pSr10
pCaso,.pSrro

Typel

Type II

2.20 (±0.06)
2.30 (±0.1)
6.05 (±0.05)
6.48 (±0.06)
5.61 (±0.09)
6.10 (±0.07)
0.32 (±0.04)

4.70 (±0.3)
4.30 (±0.3)

(Fink et al., 1990)

6.07 (±0.02)
. 6.27 (±0.01)
4.76 (±0.04)

4.99 (±0.02)
1.31 (±0.04)

The values in the brackets represent the standard error of the mean
(± S.E.M.). This is expressed as the following:

SEM = un-1/~n
(Fink et al. 1 1990; Stephenson et at., 1994; Lynch, Hayes, Lam, &
·. Williams, 1993; Lynch, Stephenson & Williams, 1995)
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Force per cross-sectional area (F/CSA):
This equates to the maximum activated force of Ca2• and sr2+ divided by
the cross-sectional area of the fibre. The calculations are as follows:
CSA= nr2
where:

= Pi
r = radius

1t

Force= ma
. where: m = mass (g)
a= acceleration constant (9.8m/sec2)
Force was expressed in milliNewtons per millimetres (mN/mm2) for this
study.
Parameters set by Fink et al., 1990 (in N/cm2) for normal human skeletal
muscle (Type I and II) are as follovvs:
Type I
Type II

26.1 (±2.7)
30.1 (±9.0)

Brackets represent± S.E.M.
(Fink et al., 1990)

.· 3.7

.

Limitations.

.

.

· · · The study was limited to the biopsy samples supplied by Royal Perth
Hospital.
This had several implications for the study, namely:
•

There was no control over the number of MHN, MHS or MHE samples.
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•

Biopsies from only one muscle (Vastus medialis) were available.

• · As muscle biopsies are only removed from patients undergoing elective
surgery, there was a risk of the surgery being postponed or cancelled,
thus affecting the collection of samples.
• There was no control over the quality and amount of muscle in the
received biopsy samples.
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CHAPTER4

4.1

Results

As a consequence of routine MH testing at the Department of

Neuropathology, Royal Perth Hospital, 8 biopsy samples \N8re made
available for use in this study. Of those, 6 'N8re deemed by the IVCT to be
normal (controls), whilst the remaining 2 were categorised as equivocal
(MHE). Ten individual muscle fibre segments (approximately 0.~1mm in
length) were dissected from each biopsy, resulting in a total of SO fibres
.(60 control, 20 MHE) being studied. Of the 80 fibres only 72 fibres (57
control, 15 MHE) were analysed, as the remaining 8 fibres (3 control, 5
MHE) v.,ere unresponsive. This may have been due to fibre damage during
dissection and mounting in the apparatus, or during the original biopsy
removal.

. Normal (Control) Fibres
Of the 57 fibres collated, only 45 could be classified as either Type I (slowtwitchl fihres or Type II (fast-twitch) fibres according to the parameters
defined by Fink et al. (1990) (see Section 3.6 p.40). Fifteen fibres were
classified as Type I (Table 4.1 ). vvhere the slope values showed that the

force-pCa (nca) and force-pSr (ns,) curves were relatively shallow (nca, nsr
<2) (Figure 4.1 ). The fibres showed a greater than .normal sensitivity
(pCas, - pSra, = 0.92) compared to the results reported by Fink et al.
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(1990) with a value of 0.32 (Table 3.1 p.40). The force per cross-sectional
area (F/CSA) generated by strontium (Sr•) was four times greater than
that of calcium (Ca2•). The other thirty fibres were classified as Type II
fibres (Table 4.1 ). The force-pea and force-pSr curves were relatively
.steep (>2) (Figure 4.3) and sensitivity to calcium and strontium was less
than that of the Type I fibres with a value of --0.62. The F/CSA was greater
in sr• than it was for ca2•.

The other 12 fibres could not be categorised as either fast-·or slow-twitch
fibres, as these fibres displayed unusual or mixed characteristics. Although
the mean slope values displayed in Table 4.1 are charaderistic of fast
twitch fibres, many individual fibres displayed shallow

nea

curves (slope

values from 1 to 2) and very steep nsr curves (slope values as either 1 or
3) (Figure 4.5). The reverse occasionally occurred where the ca2• curves
were steeper than the

sr2• curves.

These fibres also showed an average

· sensitivity of 1.29 (pCasi - pSrro), and the F/CSA for

sr2• was three times

. greater than that of ca2•.

MHEFibres

Of the 15 fibres analysed only 5 could be categorized as being either fast
or slow twitch, of which four fibres were classified as Type I (Table 4.1).
The force-pea (<1.40; statistical significance P<0.1) and force-pSr curves
(ns, <2.13) were relatively shallow (Figure 4.2), and· the fibres were
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generally less sensitive than the controls giving a value of pCaso - pSrm =
. -3.01. The·. F/CSA was far greater in the

sr2•

series (63.61mN/mm2;

statistical significance P<0.1) than in the ca2• series (15.13mN/mm2) but
overall less than the controls. Only one fibre could be categorised as a
fast-twitch fibre (Table 4.1 ), however the nca and

ns, curves were steeper

(2.13 and 3.37 respectively) (Figure 4.4). The sensitivity of this fibre was
less than that of the control fibres, giving a value of -1.06 (pCas:, - pSrm).
The F/CSA generated was more in ca2• than

sr2•

(24.87mN/mm2 and

16.51 mN/mm2 respectively) but overall less than the control fibres.

There were 10 fibres of mixed characteristics (Table 4.1) where the forcepCa curves were generally shallow (nea<2; statistical significance P<0.1)
and the force-pSr cuNes were generally very steep (n&>2.5) (Figure 4.6).
These fibres were less sensitive to ca2• and

sr• (pCBs> - pSrro = 1.52)

than that of the control mixed fibres, and the F/CSA by

sr2+

(68.97

·mN/mm2) was greater than that of the Ca2+ (43.06 mN/mm2) ..

Comparisons
For Type I fibres (see Figures 4.1 & 4.2), the values of nca, pCas:,, pCa10
and F/CSA (both Ca2• and Sr+) for control fibres were greater than for the
equivocals. The equivocal fibres YJere more sensitve than the controls for
nSr, pSrm and pSr10. However, the equivocals responded better to the

sr2•

solution than the Ca2•1 but the controls were overall more sensitive to the
two act!vating ions (Table 4.1 ). Statistically, there 'M:lre significant
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differences for

nea. ns, and F/CSA for sr2• (P<0.1) between the controls

and the MHE fibres.

For Type II fibres (see Figures 4.3 & 4.4), the values of

nca, F/CSA (Ca2•

and Sr2+) and sensitivity (pCas,.pSrro) for control fibres were greater than
for the_ equivocals. The equivocals Y1ere greater than the controls for slope
(ns,), activation threshold (pCa10 and pSr10) and relative sensitivity (pCasc,
and pSrro) to each activating ion (Table 4.1). This group could not be
statistically analysed due to only one MHE fibre being found.

For the mixed fibre group (see Figures 4.5 & 4.6), the controls were more
sensitive ·10 nca, pCa10 and F/CSA

csr2·).

The ;equivocals were more

.· sensitive to nSr, pCa10. and relative sensitivity to each activating ion (pCaa,
·and pSr50). Overall, the MHE fibres were more sensitive {pCaro-pSroo) than
the controls (Table 4.1 ). Statistically, there were significant differenc:es for

nea, nar and pCa,o (P<0.1 ).

Table 4. 1.

Contractile parameters of control and MHE-skeletal muscle fibre types

Type I

Mixed:

Type II

Control

MHE

Control

MHE

Control

MHE

15

4

30

1

12

10

nca.

1.75 ±0.09

1.40 ±0.19*

2.82 ±0.97 -

2.13

2.57 ±0.28

1.57 ±0.13*

pCaao

7.43 ±1.25

4.90 ±0.61

5.10 ±0.19

5.49

5.20 ±0.28

5.74 ±0.33

pCa10
F/CSA

8.00 ±1.26

5.63 ±0.70

5.45 ±0.19

5.93

5.61 ±0.29

6.38 ±0.35*

50.83 ±10.85

15.13 ±3.30

79.20 ±14.94

24.87

41.65 ±12.33

43.06 ±10.30

ns,

1.82 ±0.12

2.13 ±0.11*

2.78 ±0.10

3.37

2.14 ±0.25

3.16 ±0.40*

pSrso

6.52 ±0.58

7.90±0.94

5.73 ±0.38

6.55

3.90 ±0.24

4.22 ±0.42

pSr10
F/CSA

7.08 ±0.56

8.35±0.92

6.08 ±0.39

6.83

4.42 ±0.26

4.55 ±0.43

200.53 ±52.41

63.61 ±22.44*

173.31 ±33.97

16.51

127.86 ±44.75

68.97 ±35.41

0.92 ±1.24

-3.01 ±1.33

-0.62 ±0.43

-1.06

1.29 ±0.43

1.52 ±0.59

samples (n)

pCa1cr·pSrso

Data are represented as mean ±S.E.M.
*Denotes statlstlcal significance at P<0.1
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4.2

Discussion

The aim of this study was to compare the djfferences between normal
(control) human skeletal muscle and MH positive (MHS) skeletal muscle.
As no actual MHS muscle was available, only muscle classified as MH
equivocal (MHE) was used.

The skinned muscle fibre technic;'_ e (used in this study) identifies the
contractile kinetics of single skeletal muscle fibres to exogenous calcium
and strontium ion activation. Differences in the kinetics of responses to
Ca2+ can indicate functional differences of the contractile proteins (myosin
S1 subfragment) 1 whereas differences in the kinetics of responses to

sr2+

can indicate functional differences of the regulatory proteins (troponin and
tropomyosin) (Stephenson et al., 1994).

The MHE Type I fibres displayed greater sensitivity to

sr2+ (pSrro

7.90)

vmich suggests that there are functional differences in the regulatory
proteins, whereas the MHE mixed fibres were more sensitive to Ca2+
(pCaro 5.74) which is indicative of a greater reactivity in the contractile
proteins as well. The MHE Type II fibre showed no significant differences
in sensitivity to either ion as it was almost identical in slope and lateral shift
to the Type II control fibres.
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The most noticeable differences between the MHE muscle and the control
muscle, were observed during the testing phase on the Maclab system.
Most of the MHE fihres were more sensitive to the weaker Ca2+and

sr2+

solutions resulting in stronger contractions, Ykiereas the normal muscle
was unresponsive. However, these effects on the MacLab could not be
reproduced in Delta Graph as the calculation of the Relative Force
normalised these values.

The F/CSA generated by the control fibres was generally greater than that

of the equivocals for both Ca2+and

sr2+.

As fibre diameter is usually

greater in MHS muscle than that of normal muscle (Lane, 1996), equivocal
muscle has not been measured in any published studies, therefore F/CSA
is unknown in these cases. However, there was a negative statistical
significance (F/CSA P<0.1) between the Type I fibres for MHE and
controls during sr2+ adivation.

The skinned muscle fibre technique (involving Ca2+ and

sr2+)

has been

used extensively in the research of Duchenne Muscular Dystrophy (DMD)
in both humans and rodents. In comparison to the human DMD contractile
parameters performed by Fink et al. (1990), both the controls and MHE
fibres (fast and slow fibres) were more sensitive to

sr2+

than to Ca2+. In

comparison to normal mammal skeletal muscle (Wilson & Stephenson,
1990), again both the controls and MHE fibres were more sensitive to

sr2+,

notably pSrm and pSr10. Normal rat soleus muscle however VAS slightly
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different (Stephenson et al., 1994). The controls and MHE fibres were
more sensitive to pCas:, and pSrw (fast and slow fibres) than just one type
of ion. On the whole, the slope parameters (nca and nsr) for all these
examples (human DMD, mammal and rat) were unique to each case, and
rarely did the controls and MHE fibres (from this study) have similar
values.

The caffeine skinned muscle fibre technique conducted by

Britt et al.

(1982), involved only the chemical disruption of the sarcolemma. In this
study, they were testing the ca2• release from the SR on exposure to
caffeine. They found that this technique provided more information about
the calcium release mechanism of the intact SR than that of the IVCT.
Takagi, Sunohara & Nonaka (1980) found in a similar study that the
caffeine contracture threshold was lower in MHS muscle fibres than for
normal muscle fibres.

Fibre type composition in human MH is rarely tested, however a study
compiled by Heiman-Patterson, Fletcher, Rosenberg & Tahmoush ( 1987)
found that fibre type profiles and MH did not correlate. The same also
applied in fibre studies conduded in porcine stress syndrome (PSS).
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4.3

Conclusion

The contractile and regulatory proteins are all interconnected with noncontractile proteins to fonn a complex cytoskeleton that holds and
stabilises the muscle fibre during relaxation and contraction (Sugita, 1997).
The non-contractile protein dystrophin binds to the actin filament
(regulatory protein). Dystrophin also binds to the inner and outer
membrane, therefore playing an important role in the stabilisation of the
muscle cell (Sugita, 1997). In response to the first hypothesis: Individual

MH muscle fibres display differing kinetics of contraction to exogenous
calcium and strontium ion activation than individual muscle fibres in normal
(control) human muscle, both the contractile and regulatory proteins
appeared to be affected by this disease. Therefore, this would impact on
the mechanics of the Mole muscle fibre, such as making it unstable
during contraction. However, to determine if these two proteins are
affected, positive MH muscle needs to be examined to draw a definite
conclusion. For the second hypothesis: The force per cross-sectional area

generated by MH muscle fibres is different to that of normal (control)
muscle, the FICSA generated by the MHE muscle fibres was less than that
of the control muscle. However the Type I and mixed fibres did display
greater FICSA to
three fibre types.

sr2+ rather than to

Ca2+, as did the control fibres in all
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The main problem with this study was the availability of muscle samples.
The majority of the biopsies 'N8re performed for other reasons than a
family history of MH. For example, biopsies were performed for unusual
reactions to a previously administered general anaesthetic such as raised
blood carbon dioxide levels. Erring on the side of caution, the hospital had
to investigate all unusual reactions if further elective surgery was required.
Other problems encountered were the cancellation of surgery six times in
the period of muscle testing and the status of every individual not being
knovvn on the day of admission. Therefore obtaining positive MH biopsies
was unpredictable. Also, accessibility to the genetic information of the
individual (if they were from an MH family) was unobtainable for this study.

4.4

Further developments

Although this study provided limited results, the skinned fibre method
using caffeine has been previously applied to this disease and has shown
some promising results. If this method could be refined (using exO'i;ienous

cti-•, sr2•,

caffeine and possibly ryanodine on intact as well as skinned

fibres), then the technique could be used as a replacement to the IVCT. If
so, the benefits to the patient (in terms of muscle biopsies) and the
community at large could be a positive step forward.
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Table A1. 1 Kreb's~Ringer Solution
NaCl
l<CI
MgS04
KH2P04
Glucose
NaHC03
CaCl2H20
pH

118.1 mmol L-1
3.4 mmol L-1
0.8 mmol L-1
1.2 mmol L- 1
11.1 mmol L-1
25.0 mmol L-1
2.5 mmol L-1
7.4

(European Malignant Hyperpyrexia Group, 1984)

Table A 1.2 Relaxing Solution I
HEPESa
MgCl2
EGTAb
NaAzide
Caffeine
ATPc
pH

60mM
1mM
50mM
1mM

1OmM
BmM
7.1

Relaxing Solution I & 50% Glycerol:
Same solution components as Table A 1.2 made up to 1OOmls plus
1OOmls of glycerol.
1

Table A1.3 Relaxing Solution Ill
HEPES8
MgCl2
HDTAd
NaAzide
Caffeine

60mM
1mM
50mM

1mM
10mM

ATP0

BmM

pH

7.1
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Table A1.4 Calcium Solution

HEPES'

CaCO:,
M9Cl2
EGTA•

NaAzide
Caffeine
ATP'
pH

60mM
48.5mM
1mM
50mM
1mM
10mM
8mM
7.1

NB. Solutions of varying concentration were made by mixing the above with Relaxing
Solution I

Table A1.5 Strontium Solution

HEPES'

SrCO:,
MgCl2
EGTA•

NaAzide
Caffeine
ATP'
pH

60mM
40mM
1mM
50mM
1mM
10mM
8mM
7.1

NB. Solutions of varying concentration were made by mixing the above with Relaxing
Solution I

Legend:
•
•
'
•

HEPES: N-(2-hydroxyethyl] piperazine-N'-[2-ethanesulfonic acid]
EGTA: ethyleneglycol-bis(J3-aminoethylelher)-N,N,N',N',-tetraacetate
ATP: adenosine 5-triphosphate
HDTA: hexamethylenediamine-N, N, N' ,N'-tetraacetate
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PATIENT CONSENT FORM

CONSENT FOR THE

use OF BIOPSY TISSUE FOR DISEASE RESEARCH

of........................................................................................................................
hereby give permission for a section cf th:s muscle biopsy to be used in

disease research.

I understand that only !issue not required for the '.esting procedures for which
the bicpsy was taken will be used for rcse.:lrch purposes.

I realise that this permission can be withdrawn at any time.
The purpose of thls consent form has been explained to

me.

Signature: .........................................................
Dated: ...................................... .

Witness daclaration

1, ........................................................................................................................
have read over and explained to the consenting party the- purpose cf this
consent and they affixed lheir signature in my presence.

Witness signature.................................................. .

On ............................ .

